FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.
Francis R.W. Godwin
Advertisement
Francis R.W. Godwin, MBA, is office director, OMQ, OC, and CDER, at FDA.
Articles by Francis R.W. Godwin
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
3
The BioPharm Brief: Survival Gains, a Modest ADC Win, and CAR-T in Multiple Sclerosis
4
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
5